Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02322879 · ClinicalTrials.gov registry record · Phase 4
Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing
A Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT02322879 is a Phase 4 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 21 participants.
The verdict
NCT02322879, a Phase 4 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
A purpose of this protocol is to is to compare the metabolites of the toxic bioactivating pathway after acetaminophen alone or acetaminophen followed by Propylene Glycol (PG) and to determine if it prevents the formation of the toxic metabolites of acetaminophen.
Interventions
- OTHER Washout
- DRUG First Treatment Period
- DRUG Second Treatment Period
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02322879
The ClinicalTrials.gov registry entry for NCT02322879 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Washout is the first listed.
NCT02322879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02322879 about?
NCT02322879 is a clinical study titled "Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing". A purpose of this protocol is to is to compare the metabolites of the toxic bioactivating pathway after acetaminophen alone or acetaminophen followed by Propylene Glycol (PG) and to determine if it prevents the formation of the toxic metabolites of acetaminophen.
What is the current status of trial NCT02322879?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2013-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02322879?
The interventions under investigation include: Washout (OTHER), First Treatment Period (DRUG), Second Treatment Period (DRUG).
Who is sponsoring clinical trial NCT02322879?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.